Deferasirox

Deferasirox is an orally active tridentate iron chelator used for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) and in non-transfusion-dependent thalassemia. It selectively binds ferric iron (Fe³⁺) forming a 2:1 (chelator:iron) complex. Mediocon Inc supplies pharmaceutical-grade Deferasirox meeting USP, BP, EP, and IP standards.

Key Features

• Analgesic, antipyretic & anti-inflammatory
• USP/BP/IP compliant quality
• Widely used in cardiovascular therapy
• Suitable for tablet and effervescent formulations

Applications

• Transfusion-dependent iron overload
• Beta-thalassemia & sickle cell disease
• Non-transfusion-dependent thalassemia syndromes
• Myelodysplastic syndromes (MDS) with transfusion

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings